The National Institute for Health and Care Excellence has published a draft guideline on polyendocrine metabolic ovarian syndrome, or PMOS, saying the condition should be diagnosed sooner and managed with an annual review to track symptoms, treatment and long-term health risks.
The recommendation, published for public consultation on 1 July 2026, is aimed at improving care for people living with the condition and reducing delays in diagnosis. NICE said the draft guideline would remain open for feedback from healthcare professionals, patients and the public until 11 August 2026.
What the draft guidance says
According to NICE, the proposed approach would encourage earlier recognition of PMOS and more regular follow-up once a diagnosis has been made. The annual review is intended to monitor symptoms, treatment and longer-term risks associated with the condition.
The draft guidance forms part of NICE’s wider effort to improve the quality and consistency of care across the NHS, especially where conditions may be under-recognised or managed unevenly between services.
Why the issue matters in the NHS
Earlier diagnosis can be important in conditions that are difficult to identify, since delays may affect symptom control and long-term outcomes. NICE’s proposal signals a push toward more structured care, with a clearer pathway for review and ongoing monitoring.
The consultation gives clinicians and patients a chance to shape the final version before any guidance is settled. If adopted, the recommendations could help standardise how PMOS is identified and followed up in routine practice.
More details on the consultation are available from NICE, which published the draft guideline on 1 July 2026. NICE draft guideline
A consultation open until mid-August
The consultation period runs through 11 August 2026, making this a live policy development rather than a final clinical recommendation. NICE invited comments from across the health system before confirming the next steps.
If the final guidance reflects the draft, PMOS care in the NHS could become more proactive, with earlier diagnosis and a routine annual review built into management plans.
